Physician profile
Harold Bregman
NPI 1952381253
$505.88
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $20.18 · 2021: $43.40.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $124.92 | 2019 | |
| Fresenius USA Marketing, INC. | $104.34 | 2019 | |
| Nxstage Medical, INC. | $79.28 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $66.64 | 2019-2021 | |
| Daiichi Sankyo INC. | $48.24 | 2019 | |
| Vifor Pharma, INC. | $44.86 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $21.04 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Bregman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.